Cite

    Flenner, F. et al. (2016). Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy. Cardiovascular research. pp. 90-102. [Online].